RxDoctor Payments Data

David Handshoe, MD

Pulmonary Disease · Summerville, SCNPI 1659371755

Payments from drug & device makers

$9,771in general payments, 2019–2025

Across 441 payments — averaging $22.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • GSK$973
  • Sanofi$776
  • Boehringer Ingelheim$548
  • Insmed, Inc.$478
  • Genentech USA, Inc.$448
  • plus $5K from 38 others

What the payments were for

  • Food & beverage$9,59698%
  • Education$1752%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,771 in reported general payments places this provider in the 65th percentile of 192 pulmonary disease providers in South Carolina.

See all pulmonary disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$109,619
Medicare patients
449
Services billed
1,313

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter266$218,920
OfevNintedanib Esylate13$169,958
Breztri AerosphereBudesonide/Glycopyr/Formoterol72$60,804
Breo ElliptaFluticasone/Vilanterol92$47,911
Spiriva RespimatTiotropium Bromide30$15,954
EliquisApixaban13$15,176
Advair HfaFluticasone Propion/Salmeterol27$13,329
Incruse ElliptaUmeclidinium Bromide16$10,918
Albuterol Sulfate HfaAlbuterol Sulfate297$9,483
Wixela InhubFluticasone Propion/Salmeterol58$8,485
SymbicortBudesonide/Formoterol Fumarate18$6,382
Fluticasone-SalmeterolFluticasone Propion/Salmeterol20$3,899
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate13$3,222
BreynaBudesonide/Formoterol Fumarate14$2,224
Ventolin HfaAlbuterol Sulfate15$1,248

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$973$277,750374 claims
Boehringer IngelheimOfev, Spiriva Respimat$548$185,91243 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,363$67,18690 claims
PfizerEliquis$138$15,17613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 192 pulmonary disease providers in South Carolina.

Other pulmonary disease in Summerville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →